首页|"丹黄三方案"分度治疗轻、中、重度子宫腺肌病的临床研究

"丹黄三方案"分度治疗轻、中、重度子宫腺肌病的临床研究

扫码查看
目的 探讨"丹黄三方案"分度治疗轻、中、重度子宫腺肌病的临床效果。方法 根据MD将100例患者分为轻(17例)、中(32例)、重度(51例)三度,分别采用丹黄、丹米、丹瑞方案治疗,3个疗程后再根据MD分度,将重度降至中度者采用丹米方案治疗,中、重度降至轻度和原发轻度患者采用丹黄方案治疗。对比治疗前后MD、UV、CA-125、VAS,评价丹黄、丹米、丹瑞三方案分度治疗轻、中、重度子宫腺肌病的临床效果。结果 51例重度患者降至中度35例(降调组)、轻度16例(降调1组),患者UV、MD、CA125、VAS从治疗前的160。0 mL、43。0 mm、63。2 U/mL、8分分别降至85。5 mL、31。0 mm、14。2 U/mL、0分(P<0。05)。32例中度原发和35例降调组降至轻度分别为23、26例,追加1疗程全部降到轻度(降调2组),患者UV、MD、CA125、VAS从治疗前的135。7 mL、34。5 mm、47。7 U/mL、4。1分和88。0 mL、32。3 mm、15。3 U/mL分别降至90。7 mL、28。9 mm、12。6 U/mL、0。1分和69。6 mL、28。1 mm、6。1 U/mL(P<0。05)。17例原发、16例降调1组、67例降调2组UV、MD、CA125、VAS从治疗前的104。6 mL、25。1 mm、30。0 U/mL、2。4分;67。2 mL、27。0 mm、6。3 U/mL;78。9 mL、26。2 mm、7。63 U/mL分别降至68。9 mL、22。2 mm、11。2 U/mL、0分;62。9 mL、23。3 mm、5。27 U/mL和78。9 mL、26。2 mm、7。63 U/mL(P<0。05)。结论 "丹黄三方案"分度治疗子宫腺肌病效果显著,为子宫腺肌病无创治疗提供了一套完整治疗方案,值得临床借鉴与深入研究。
Clinical study on the grading treatment of mild,moderate and severe adenomyosis by using"Danhuang three scheme"
Objective To investigate the clinical effect of"three regimens of Danhuang"in the treatment of mild,moderate and severe adenomyosis.Methods According to MD,100 patients were divided into three grades:mild (17 cases),moderate (32 cases),severe (51 cases),and were treated with Danhuang,Danmi,and Danrui,respectively.After 3 courses of treatment,according to MD grading,patients turned to moderate from severe grade were treated with Danmi and patients turned to mild from moderate and severe grades and pa-tients in the primary mild grade were treated with Danhuang.MD,UV,CA-125 and VAS before and after treat-ment were compared to evaluate the clinical effect of Danhuang,Danmi and Danrui in the treatment of mild,moderate and severe adenomyosis.Results For the 51 cases of severe patients,35 became better after treatment and turned to the moderate grade (descending group),and 16 bettered to the mild grade (descending group 1 ). UV,MD,CA125 and VAS decreased from 160.0 ml,43.0 mm,63.2 U/ml and 8 before treatment to 85.5 ml,31.0 mm,14.2 U/ml and 0 points,respectively (P<0.05).For the 32 cases of primary moderate patients and 35 cases of descending group,23 cases and 26 cases became better after treatment and turned to the mild grade,respectively,and all of them bettered to mild (descending group 2)after an additional course of treatment.UV,MD,CA125 and VAS decreased from 135.7 ml,34.5 mm,47.7 U/ml,4.1 and 88.0 ml,32.3 mm,15.3 U/ml to 90.7 ml,28.9 mm,12.6 U/ml,0.1 and 69.6 ml,28.1 mm,6.1 U/ml,respectively (P<0.05).UV,MD,CA125 and VAS in 17 cases of primary mild grade,16 cases of down-modulation 1 group and 67 cases of down-modulation 2 group were reduced from 104.6 ml,25.1 mm,30.0 U/ml and 2.4;67.2 ml,27.0 mm,and 6.3 U/ml;78.9 ml,26.2 mm,and 7.63 U/ml before treatment to 68.9 ml,22.2 mm,11.2 U/ml,and 0;62.9 ml,23.3 mm,and 5.27 U/ml;78.9 ml,26.2 mm,and 7.63 U/ml,respectively (P<0.05 ). Conclusion The"Danhuang three program"has a remarkable effect on the grading treatment of adenomyopathy. This study provides a complete treatment plan for the non-invasive treatment of adenomyopathy,which is worthy of clinical reference and further study.

adenomyosisDanhuang Quyu capsulesmifepristoneliangbingruilingrading therapy

苏远华、梁志刚、任晓艳、肖雁冰

展开 >

贵州航天医院 妇科,贵州 遵义 563000

遵义市妇幼保健院 妇科,贵州 遵义 563000

子宫腺肌病 丹黄祛瘀胶囊 米非司酮 亮丙瑞林 分度治疗

2024

遵义医科大学学报
遵义医科大学

遵义医科大学学报

CSTPCD
ISSN:2096-8159
年,卷(期):2024.47(12)